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Background/aim: This study aimed to examine the change in the etiology of hospital infections with restricting and releasing of group
2 carbapenems (G2C) (meropenem/imipenem/doripenem).
Materials and methods: This study was planned in three periods. Study period 1 (SP-1): Carbapenems were prescribed without
restriction by infectious disease specialists. SP-2: G2C prescription was restricted. SP-3: Carbapenem prescription was released.
Results: In total, 4443 cases [1053 in SP-1 (23.7%), 1332 in SP-2 (29.9%), and 2085 in SP-3 (46.9%)] were included in the study. Infection
rates were 11%, 6.5%, and 7.9% in SP-1, SP-2, and SP-3, respectively (P = 0.001). Acinetobacter spp.-related hospital infection rates were
3.9%, 1.2%, and 1.8%, in SP-1, SP-2, and SP-3, respectively (P = 0.0001). Infection related mortality in SP-1, SP-2, and SP-3 was 7.3%,
5%, and 3.8%, respectively (P = 0.001).
Conclusion: Hospital-acquired Acinetobacter infections, antibiotic consumption, and infection-related mortality were decreased
significantly with the restriction of G2C. Positive behaviors that were obtained during the restricted period were continued with release
of restriction.
Key words: Restriction of carbapenem, antibiotic stewardships, hospital-acquired Acinetobacter infections, infection related mortality

1. Introduction
Antibiotics are some of the most important drugs of the
last century. However, the treatment of drug-resistant
infections is quite difficult nowadays. The unnecessary use
of antibiotics led to the increase and spread of multidrugresistant bacteria (1). The use of antibiotics, treatment
costs, and antibacterial resistance are lower in countries
in which there is rational antibiotic consumption (2,3).
By contrast, in countries in which there is no control
over the use of antibiotics, both resistant microorganisms
and infections caused by these resistant microorganisms
increase more and more (4).
Acinetobacter baumannii, a nonfermentative and gramnegative bacterium, attracts attention due to its multidrug
resistance. It causes significant nosocomial infections,
especially in intensive care units (ICUs) (5). In recent
years, reports of hospital infections caused by multidrug
resistant Acinetobacter baumannii have been on the rise
(6,7). Lately, a lot of Acinetobacter-related infections
have been reported in Turkey. Carbapenem resistance in
Acinetobacter baumannii infections has increased over the
years and reached 90.7% in 2014 (8).
* Correspondence: ertugrulguclu@hotmail.com

The use of carbapenem in our hospitals is quite
excessive (9). The relationship between carbapenem use
and resistant Acinetobacter has been investigated by many
researchers (10). The reduction in the nonfermentative
gram-negative bacilli colonization/infection by restricting
carbapenem has been shown in many studies (4,11).
In the first part of this study, we published the effect of
carbapenem restriction on Acinetobacter epidemiology
in ICUs (10). In the current study, we added a new and
different period, and extended the duration of the second
period of the first study. In the second part of the study, we
aimed to investigate the effect of removing the restriction on
physician behavior, mortality, G2C consumption, changes
in antibiotic use between restriction and restriction-free
period, and its effect on resistant Acinetobacter infections.
2. Materials and methods
2.1. Study design and data collection
This study was conducted at the Sakarya University
Education and Training Hospital. The hospital has three
separate campuses. There are a total of 956 patient beds
in these campuses and 137 of them are in the ICU. This

361

KARABAY et al. / Turk J Med Sci
study was carried out over three periods on 25 beds of
the anesthesia and reanimation ICU (ARICU) and 9 beds
of the neurology ICU (NICU), between May 2011 and
December 2015. All patients in these ICUs were followed
daily by infectious disease and clinical microbiology
specialists (IDCMS). In each period, similar infection
control measures were performed. All data were obtained
from patient files retrospectively.
Infection-related mortality for each period was
calculated as patients who died after hospital infection
diagnosis divided by number of patients hospitalized in
the ICU during the same period.
2.2. Antibiotic prescription
Antibiotics were divided into two groups due to
reimbursement restrictions in Turkey: restricted antibiotics
(reimbursed when prescribed only by infectious disease
specialists) and unrestricted antibiotics (reimbursed
when prescribed by any doctor). Restricted antibiotics
were imipenem, meropenem, doripenem, ertapenem,
vancomycin,
teicoplanin,
daptomycin,
linezolid,
colistin, piperacillin/tazobactam, sulbactam, cefepime,
cefoperazone/sulbactam, intravenous quinolones, and
tigecycline.
Sakarya University Education and Training Hospital
has a hospital information management system.
Antibiotics were prescribed only by IDCMS, according to
legal regulations in Turkey.
2.3. Study periods
The study was conducted in three periods. All patients
were examined in the ICU before antibiotic prescription
during all periods.
Study period 1 (SP-1): May 2011–February 2012
During this period, G2C was prescribed by IDCMS
working in the hospital without restriction.
Study period 2 (SP-2): May 2012–September 2013
The use of G2C in SP-2 was restricted either in
empirical use or after obtaining antibiogram results.
According to the antibiogram results, G2C was not used
if there was a chance of using other antibiotics other
than G2C. Ertapenem, a carbapenem outside G2C, was
prescribed freely.
Study period 3 (SP-3): October 2013–December 2015
During this period, G2C restriction was removed
and IDCMS represcribed all carbapenems without any
restriction for patients in need. In other words, antibiotic
prescription rules returned to the rules in SP-1.
2.4. Antibiotic consumption data
The consumption of all antibiotics was obtained on a
box basis from the data on the hospital information
management system. According to the definition of
daily defined dose (DDD) reported by the World Health
Organization, antibiotics are transformed into value of
DDD (12).
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2.5. Inclusion criteria
All patients who were treated in ARICU and NICU in
our hospital were included in the study. Infection and
colonization were determined according to the Centers
for Disease Control (CDC) hospital infection diagnostic
criteria as defined elsewhere (13).
2.6. Exclusion criteria
Patients who were under 18 years old were excluded from
the study.
2.7. Infection control procedures
Infection control procedures include avoiding use of
unnecessary invasive applications, compliance to aseptic
and antiseptic procedures during medical practice, removal
of unnecessary invasive devices as soon as possible, and
compliance with hand hygiene. These procedures were
implemented during all study periods (14). Necessary
cultures were obtained from patients in terms of fever, any
changes in general condition, and suspicion of infection
in the ICU.
2.8. Ethical approval
The ethical approval for this study was obtained from the
Sakarya University Faculty of Medicine Ethics Committee
on 23 December 2014 (No: 71522473/050.01.04/1).
2.9. Statistical analysis
Data were evaluated using the computer program Epiinfo (CDC, Atlanta, GA, USA). Student’s t-test was used
to evaluate the quantitative variables; chi-square and
Yates corrected chi-square tests were used to evaluate the
qualitative data. P < 0.05 was considered significant.
3. Results
This study was carried out during three periods: 1053
patients were tracked during SP-1, 1322 patients were
tracked during SP-2, and 2085 patients were tracked during
SP-3. Patient and microbiological data are summarized in
the Table.
Among the study periods, SP-2 had the lowest hospital
infection rate [11.4% during SP-1, 6% during SP-2, and
7.8% during SP-3 (P < 0.001)]. The density of hospital
infections during SP-1 = 19.6; during SP-2 = 7.6, and
during SP-3 = 7.1 (P < 0.001).
The consumption amount of antibiotics is shown
in Figure 1. While there was a significant difference in
antibiotic consumption between SP-1 and SP-2 (P = 0.01),
there was no difference between SP-2 and SP-3 (P > 0.05)
(Figure 1).
The distribution of antibiotic consumption according
to study periods is given in Figure 2. In the restriction
period of G2C, the use of certain antibiotics (piperacillin/
tazobactam and colistin) has increased.
The distribution of pathogens is given in Figure 3.
While a significant difference was found in terms of
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Figure 1. Antibiotic consumption according to periods.
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Figure 2. Distribution antibiotics used during study periods
(DDD/patient day × 1000).
SAM: ampicillin/sulbactam; G2C: group 2 carbapenem; ERT: ertapenem; TZP: piperacillin/tazobactam; CAZ: ceftazidime; CRO:
Ceftriaxone; AG: aminoglycosides; COL: Colistin; VAN: Vancomycin; TGC: Tigecycline.
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Figure 3. Distribution of bacterial agents.

Acinetobacter, Klebsiella, Pseudomonas, and Candida,
there was no difference among the others.
Infection-related mortality was 7.3% during SP-1,
while it was 5% (P = 0.02, OR: 1.49) during SP-2, and 3.8%
during SP-3 (P < 0.001) (Table).
4. Discussion
Resistant infections are one of the leading causes of
mortality in the ICU (15,16). Many strategies have been
tried to deal with this problem (17). In one of these
strategies, antibiotic stewardships have been applied, i.e.
limited use of antibiotics, rational use of antibiotics, and
use of antibiotics with rotation (18). The usage of broad
spectrum antibiotics has caused collateral damage in the

hospital bacterial flora. Limitation of broad spectrum
antibiotic usage in a hospital may decrease the percentage
of antibiotic-resistant bacteria. We hypothesized that
antibiotic restriction during defined periods can change
hospital infection pathogens in the ICU as well as physician
behaviors. Moreover, antibiotic rotation strategies are
needed to reduce antimicrobial resistance. For this reason,
we have used this strategy in our hospital for more than 8
years.
In this study, antibiotic restriction and later removal of
the restriction have been investigated to determine what
kind of behavior it causes in physicians who prescribe
antibiotics (19). The study consisted of three periods.
Carbapenem was used freely for 10 months (SP-1). After
this period, G2C was restricted for 17 months (SP-2), and
then all carbapenem prescription was released again for 27
months (SP-3). According to the basic results of this study,
there was a decrease in the frequency of Acinetobacter,
Pseudomonas, and Klebsiella spp.-related infections
during the restricted period. Moreover, the usage of
broad spectrum antibiotics during the restricted period
and during the released restriction period decreased as
well. After releasing the restriction, consumption of G2C
did not increase, without any change in infection-related
mortality.
The most striking finding of this study is that reduction
in antibiotic consumption with restriction continues to
decrease even when the restriction is removed. The use
of G2C continued to decline both during the period of
restriction and during the release of the restriction. In
contrast, both during the restriction period and during
the releasing of the restriction period, the use of colistin,
piperacillin/tazobactam, and ertapenem increased. The
increase in colistin consumption might be related to G2C
limitation. Clinicians may choose to prescribe colistin
during the G2C period due to antipseudomonal and antiAcinetobacter effect of colistin. Increased use of colistin in
the SP-3 may be related to habits gained with colistin use.
Interestingly, quinolone consumption decreased without
restriction. In ICUs in our center, quinolones are generally
used in combination with G2C. We think that physicians
who cannot use G2C during the restriction period do not
include quinolones in the treatment either. Therefore, the
restriction of carbapenems might reduce consumption of
combined drugs such as quinolones or aminoglycosides as
well.
Although all antibiotic restrictions were removed
in SP-3, it was observed that the doctors who have the
ability to prescribe any antibiotic freely continue to restrict
themselves. During this period, while IDCMS were able
to prescribe G2C, they still did not do so. We think that
this can depend on the belief that treatments that do not
contain G2C are as successful as those that do. Moreover,
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Table. Hospital infections and Acinetobacter-related infection rates according to working periods.

Explanation

Study period 1
n (%)
(density ‰)

Study period 2
n (%)
(density ‰)

Study period 3
n (%)
(density ‰)

Patients (n)

1053

1322

2085

Patient days (n)

6143

10444

22827

Hospital infections (n)

121 (11.4) (19.6)

80 (6.0) (7.6)

164 (7.8) (7.1)

0.0001

Ventilator-associated pneumonia

56 (5.3) (18.9)

32 (2.4) (6.1)

13 (0.6) (1.1)

0.001

Urinary catheter-related urinary tract infection

23(2.1) (4.0)

7 (0.5) (0.7)

23 (1.1) (1.0)

0.001

Central venous catheter-related bloodstream infection

12 (1.1) (4.1)

25 (1.8) (4.2)

102 (4.8) (7.2)

0.001

Infection-relationship mortality rates

77 (7.3) (12.5)

67 (5.0) (6.4)

80 (3.8) (3.5)

0.0001

Acinetobacter baumannii infections

42 (3.9) (6.8)

17 (1.2) (1.6)

38 (1.8) (1.6)

0.0001

Klebsiella pneumoniae infections

19 (1.8) (3.0)

10 (0.7) (9.5)

46 (2.2) (2.0)

0.005

Pseudomonas aeruginosa infections

21 (2.0) (3.4)

15 (1.1) (1.4)

19 (0.9) (0.8)

0.032

Candida spp. infections

3 (0.3) (0.1)

7 (0.5) (0.6)

38 (1.8) (1.6)

0.001

Escherichia coli infections

9 (0.9) (1.4)

7 (0.5) (0.6)

7 (0.3) (0.3)

0.159

Enterobacter spp. infections

5 (0.5) (0.8)

9 (0.7) (0.8)

5 (0.2) (0.2)

0.151

Enterococcus spp. infections

9 (0.9) (1.4)

3 (0.2) (0.2)

12 (0.6) (0.5)

0.110

Vancomycin resistant Enterococcus spp. infections

2 (0.1) (0.1)

0 (0.0) (0.0)

2 (0.09) (0.08)

0.304

Coagulase negative staphylococcus infections

5 (0.5) (0.1)

7 (0.5) (0.6)

3 (0.1) (0.1)

0.112

Serratia marcescens infections

0 (0.0) (0.0)

3 (0.2) (0.2)

3 (0.1) (0.1)

0.321

Staphylococcus aureus infections

4 (0.4) (0.1)

7 (0.5) (0.6)

2 (0.1) (0.1)

0.061

Methicillin-resistant Staphylococcus aureus infections

4 (0.4) (0.6)

5 (0.3) (0.4)

0 (0.0) (0.0)

0.019

Stenotrophomonas maltophilia infections

0 (0.0) (0.0)

1 (0.1) (0.1)

1 (0.0) (0.0)

0.685

Proteus spp. infections

1 (0.1) (0.1)

1 (0.1) (0.1)

5 (0.2) (0.2)

0.421

Citrobacter spp. infections

1 (0.1) (0.1)

0 (0.0) (0.0)

1 (0.0) (0.0)

0.552

Other streptococcus infections

0 (0.0) (0.0)

1 (0.1) (0.1)

0 (0.0) (0.0)

0.305

during SP-2, not only G2C consumption but also total
antibiotic consumption decreased. We think that these
findings are important for the rational use of antibiotics.
With the spread of this application, restriction of some
antibiotics might be implemented in antibiotic stewardship
programs (16).
We also examined total mortality, frequency of
Acinetobacter infections, and mortality from infections
other than Acinetobacter during restricted and unrestricted
periods. We found that mortality due to Acinetobacter or
non-Acinetobacter infections did not increase.
An important result of our study is that ICU
pseudomonas epidemiology is clearly influenced by
antibiotic consumption. Our results suggest that if
wide spectrum antibiotic consumption can be limited,
pseudomonas infection rate will decrease. On the other
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P-value

hand, we observed that Candida spp.-related infections
tended to increase in spite of decrease in antibiotic
consumption. We do not have a significant hypothesis
about this finding. It needs a more comprehensive
investigation.
The most important limitation of our work is that the
study design was performed retrospectively and in a single
center. If this work could be done as a multicenter study,
local differences such as training frequency, infection
control practices, and acceptance of new knowledge by
some physicians could be excluded.
Finally, hospitals should monitor antibiotic use policies
during certain periods and develop restricted formulas
based on their own observations. As a result, we think
that well-planned antibiotic restraint practices can play an
important role in encouraging rational antibiotic use.
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